top of page

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies

  • Dec 9, 2025
  • 1 min read

Updated: Dec 11, 2025

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABL/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page